

# **Surgical Mesh for Transvaginal Repair of Pelvic Organ Prolapse in the Anterior Vaginal Compartment**

Obstetrics and Gynecology Devices Panel of the  
Medical Advisory Committee

Kila B. Baldwin, Esq.

Kline & Specter, P.C.

February 12, 2019

The following summary of unmet needs generated June 2<sup>nd</sup> 2006 was again confirmed without any adding:

| Unmet clinical needs   | Priority (points) |
|--|-------------------|
| No shrinkage / no long-term contraction<br>Fibrosis reduction<br>Severe contraction → Dyspareunia → sexual function↓<br><i>Tension response ↓</i><br>= ↓ Sexual pain?<br>No folding of mesh<br>No rigidity | 10                |
| No vaginal distortion, normal vaginal wall, maintain sexual function, normal sexual function   | 8                 |
| Elasticity simulating physiology   | 5                 |
| No chronic pain<br>Patient comfort<br>Less erosion<br>Less vaginal mesh exposition   | 4<br>2            |
| BIO-active, "long term" - 90 days <ul style="list-style-type: none"> <li>• growth factors</li> <li>• anti-bacterial</li> <li>• hormonal</li> <li>• angiogenesis</li> </ul>                                 | 3                 |
| Better handling<br>Implantation process:<br>→ Make it easier<br>→ Correct placement<br>Simple application<br>Even simpler to apply   | 3                 |

**Ethicon Expert Meeting: Meshes for Pelvic Floor Repair**  
Friday, February 23<sup>rd</sup>, 2007; Location: Oststr. 1, Norderstedt, Meeting Room "Forum"

External Participants:

Prof. M. Cosson  
Prof. B. Klosterhalfen  
Prof. J. Deprest  
Prof. B. Jaquetin  
Dr. Arlt  
Dr. D. Miller  
Dr. K. Lobodasch

Ethicon:

Bob Roda  
Cliff Volpe  
Dave Robinson  
Axel Arnaud  
J. Flatow  
O. Berthier  
Ed Jacobs

P. Köhler  
Aida Astanl  
K. Spychaj  
P. Meier  
J. Holste  
J. Trzewik  
B. Hellhammer



"Agenda-febr Mesh Meeting.doc"

Agenda:

Highlights from the presentations and related discussion (Please see CD as well):

Introduction and update of project "LIGHTning" (P. Meier)

PM gave a quick overview of the history of the project. Project is now in development phase. Team has achieved discovery work successfully. Ultrapro is the most promising available mesh for pelvic floor repair. Further animal and clinical data has to be collected prior launch of a product to substantiate this.

PLAINTIFFS'  
TRIAL EXHIBIT  
P0785

Plaintiffs  
EXHIBIT NO. 598  
3/28/07  
A. M. MITCHELL  
ETH.MESH.02017152

HIGHLY CONFIDENTIAL  
SUBJECT TO STIPULATION AND ORDER OF CONFIDENTIALITY

P039969

# What did we learn from abdominal wall repair studies?

## ■ Mesh repair

- **Reduce the rate of recurrence** compared with traditional suture repair
- Works by both direct mechanical sealing (sublay) and induction of a scar plate formation

## ■ Several complications

associated with the use of mesh  
may be due to the **chronic inflammatory reaction** to the mesh or **a loss of compliance after degradation of the material**

## ■ Mesh shrinkage

folding and migration, may result in some cases in a **recurrent hernia** and also **pain**

Amid PK, *Hernia* 1997  
LeBlanc KA, *Hernia* 2001

Mesh shrinkage  
How to assess, prevent, how

### WORKSHOP #2

Postoperative specific complications following transvaginal mesh repair of pelvic organ prolapse: etiology, prevention and management.

L. V.  
B. F.  
B. J.  
Clerk

# TRANSVAGINAL MESH OR GRAFTS COMPARED WITH NATIVE TISSUE REPAIR FOR VAGINAL PROLAPSE (Review)

Maher C,

Transvaginal mesh or grafts compared with native tissue repair for vaginal prolapse (Review)

## Authors' conclusions

While transvaginal permanent mesh is associated with lower rates of awareness of prolapse, repeat surgery for prolapse, and prolapse on examination than native tissue repair, it is also associated with higher rates of repeat surgery for prolapse or stress urinary incontinence or mesh exposure (as a composite outcome), and with higher rates of bladder injury at surgery and de novo stress urinary incontinence. The risk-benefit profile means that transvaginal mesh has limited utility in primary surgery. While it is possible that in women with higher risk of recurrence the benefits may outweigh the risks, there is currently no evidence to support this position.

# TRANSVAGINAL MESH OR GRAFTS COMPARED WITH NATIVE TISSUE REPAIR FOR VAGINAL PROLAPSE (Review)

Maher C,

Low to moderate quality evidence suggests that there are advantages to using transvaginal mesh or grafts compared with native tissue repair, including lower rates of awareness of prolapse, repeat surgery for prolapse, and recurrent prolapse on examination. The evidence suggests that if 19% of women are aware of prolapse after native tissue repair, between 10% and 15% will be aware of prolapse after permanent mesh repair. If the rate of recurrent prolapse on examination after a native tissue repair is assumed to be 38%, the risk would be between 11% and 20% after a repair with transvaginal permanent mesh. However, there are also problems associated with

## Quality of the evidence

Overall, the quality of the evidence ranged from very low to moderate. The main limitations were poor reporting of study methods, inconsistency, and imprecision.

Cochrane Database of Systematic Reviews

## INDUSTRY SPONSORSHIP AND RESEARCH OUTCOME (REVIEW)


Lundh A

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L

### Authors' conclusions

Sponsorship of drug and device studies by the manufacturing company leads to more favorable efficacy results and conclusions than sponsorship by other sources.

# Why focus on Pelvic Floor?



**Gynecare**  
WOMEN'S HEALTH SOLUTIONS

Internal use -Ophélie Berthier  
Training November 21/22th

P040431

HIGHLY CONFIDENTIAL  
SUBJECT TO STIPULATION AND ORDER OF CONFIDENTIALITY

P040460

HIGHLY CONFIDENTIAL  
SUBJECT TO STIPULATION AND ORDER OF CONFIDENTIALITY

ETH.MESH.02283290

## What is specific to vaginal surgery ?

- Much of what we know about grafts comes from research involving the abdominal wall hernias
- Poor knowledge of the vaginal *in vivo* response to the materials
- The vagina has an **important vascularity** and **endogenous microflora** that may have an impact on **host tissue response** and **biomechanical properties** of grafts used in pelvic reconstructive

### Mesh shrinkage How to assess, prevent, how to

#### WORKSHOP #2

Postoperative specific complications following transvaginal mesh repair of pelvic organ prolapse: etiology, prevention and management.

L. Vel  
B. Fat  
B. Jac  
Clermo

P041625

P041628

- no mesh is the best mesh
  - lightweight concept with a high pore to implant area ratio

1 adopt physiological demands

## • no mesh is the best mesh

- 2007 unpublished data)
- 2. max elongation limit (< 40 % at 10 kPa (10 kN/m<sup>2</sup>= 1N/cm<sup>2</sup>) contact pressure ( var. Moritsen. 2007; Janda 2006; O'Dell 2007)
  - 1. extreme 17 kN/m<sup>2</sup> (O'Dell 2007))
- 3. min. plastically softening under stretching: Eplast < Ultrapro
- 4. shrinkage/stiffening
  - 1. pore size > 3 mm
  - 2. pore size > 1 mm under stretch (mesh + stress shielding component only)
    - stress shielding of mesh implant (duration < 7d) (Abramov 2006)
- 5. anisotropic behavior 1:2 (long:vert) (Yamada 1971; Rubod 2007)
  - 1. 8:1 (lightning)< 1:1 (Gynemesh) < 1:2 (Thunder)< 1:8 (Ultrapro)
- 6. softness pattern ( to be discussed)

## Preliminary requirements

- no mesh is the best mesh
  - lightweight concept with a high pore to implant area ratio
- 1. adopt physiological demands

# no mesh is the best mesh

- 3. min. plasticity softening under stretching
  - 1.  $E_{plast} < \text{Ultrapro}$
- 4. shrinkage/stiffening
  - 1. pore size  $> 3 \text{ mm}$
  - 2. pore size  $> 1 \text{ mm}$  under stretch (mesh + stress shielding component only)
    - stress shielding of mesh implant (duration  $< 7\text{d}$ ) (Abramov 2006)
- 5. anisotropic behavior 1:2 (long:vert) (Yamada 1971; Rubod 2007)
  - 1. 8:1 (lightning)  $< 1:1$  (Gynemesh)  $< 1:2$  (Thunder)  $< 1:8$  (Ultrapro)
- 6. softness pattern arms vs. body, Erosion prevention zone